Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN





Clinigen is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right time.




To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed. Through three businesses, Clinigen SP, Clinigen GAP, and Clinigen CTS, we acquire, license and revitalise niche, hospital-only critical care medicines, and source and supply our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.





Clinigen Clinical Trials Supply (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Clinigen Global Access Programs (GAP):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical medicines for physicians and their patients all over the world. But what is a Global Access Program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a global access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolio of larger pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases, and we specialise in revitalising them – finding new treatment areas; new markets where we can get them licensed; or, potentially, new formulations. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is being well looked after.

We are currently 100+ people, headquartered in Burton-on-Trent in the UK, with facilities in Philadelphia, US, and Tokyo, Japan, and an office in London. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while doctors and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.




http://www.clinigen.co.uk/

Clinigen: Investec increases target price from 313p to 469p reiterating its hold recommendation.

Flag on the chart showing stock is in consolidation phase. Reckon itl take off early november on a monday. Ill check my system and predict which monday. Bet I get it right.

Clinigen participating in the
BIO-Europe® Conference Vienna Nov 4-6




BIO-Europe® is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry

Then -



WODC Geneva

Geneva

14 November 2013 - 15 November 2013



ASH

New Orleans

5 December 2013 - 10 December 2013


http://www.ebdgroup.com/bioeurope/index.php

Interesting, watch out for my systems monday call. Not this monday.

In IC this week, one of thirteen red hot soaring shares.

With the consultancy business growing particularly strongly and new drugs on the roster for the coming year, there is a clear buzz about prospects.

Oh dear. Another one that has a huge sp.
BTW, didn't Directors do well to sell when it looked like a generous act....(recent News)...

Currently;- too high for me.

Even higher now, broken £5.

Clinigen Group PLC (CLIN:LSE) set a new 52-week high during today's trading session when it reached 515.00. Over this period, the share price is up 162.40%

In Shares - Pharmaceutical, biotech and medical technology spending driving trend.

Clinigen and Venn Life Sciences are both companies set to benefit from strong growth in the contract research space. The global contract research industry, which provides research services to pharmaceuticals, biotechs and medical technology companies, is set to expand 11.4% a year until 2017.. Based on these growth estimations the market will be worth $43 billion in 2017, up from $25 billion in 2012.
Clinigen , which has operations in Europe, the US, and Japan, has enjoyed phenomenal success since it went public last year (25 Sept 12) This reflects the £396 million caps stellar growth prospects with pre-tax profits set to rise 67% this year to £24.2 million from the £14.5million recorded in the 12 months to July 2013.

5 to 7 more drugs to be bought over the next 3 to 5 years say the management.

Looks like its got far further to go.

In IC - Game changers . A company with 10 bagger innovations.




Clinigen, which listed on the aim in late 2012 , must count as one of the junior markets best success stories barely a year into its stock market life. The company is a game changer not so much for what it does, which is supply drugs around the world for comparison purposes in clinical trials, but for how it has set up its business model. Simply put, there are hardly any companies in the world that combine both the supply of medicines - this is more of a wholesale function - with pharmaceutical services such regulatory advice and the selling of wholly-owned products.

Clinigen Group PLC (CLIN:LSE) set a new 52-week high during today's trading session when it reached 555.00. Over this period, the share price is up 164.39%.


As of Nov 23, 2013, the consensus forecast amongst 5 polled investment analysts covering Clinigen Group PLC advises investors to purchase equity in the company. This has been the consensus forecast since the sentiment of investment analysts improved on Nov 18, 2013. The previous consensus forecast advised that Clinigen Group PLC would outperform the market.

Clinigen Group PLC (CLIN:LSE) set a new 52-week high during today's trading session when it reached 564.00. Over this period, the share price is up 175.12%.

In Shares - Consensus expects the company to make £24.2m before tax this year, enough for 22.1p in earnings per share, a figure that leaves the stock on 23.3 times earnings . The 2.6p a share dividend offered to investors in 2013 is expected to grow to 3.3p in the year to June 2014 and 4p in the fiscal 2015.

Clinigen Group PLC (CLIN:LSE) set a new 52-week high during today's trading session when it reached 573.50. Over this period, the share price is up 179.76%.

On Friday, Clinigen Group PLC (CLIN:LSE) closed at 579.50, 0.60% below its 52-week high of 583.00, set on Dec 06, 2013.

Clinigen Group PLC (CLIN:LSE) set a new 52-week high during today's trading session when it reached 604.50. Over this period, the share price is up 201.51%.

:-))

Clinigen Group PLC (CLIN:LSE) set a new 52-week high during today's trading session when it reached 607.50. Over this period, the share price is up 205.28%.

Clinigen Group PLC (CLIN:LSE) set a new 52-week high during today's trading session when it reached 613.00. Over this period, the share price is up 172.87%.

IC today - Success of drug and consultancy divisions are powering ongoing upgrades.